Goldman Sachs
BLTE

Goldman Sachs’s Belite Bio BLTE Stock Holding History

Goldman Sachs’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Buy
105,509
+60,910
+137% +$10.2M ﹤0.01% 2600
2025
Q4 		$7.13M Buy
44,599
+40,893
+1,103% +$4.84M ﹤0.01% 3418
2025
Q3 		$274K Buy
+3,706
New +$243K ﹤0.01% 5803
2025
Q1 		– Sell
-6,326
Closed -$399K – 6078
2024
Q4 		$399K Buy
+6,326
New +$417K ﹤0.01% 5361

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's BLTE Position: Q1 2026 in Review

Goldman Sachs increased its Belite Bio (BLTE) stake by 137% in Q1 2026, buying an estimated $10.2M and bringing the position to 105,509 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

Goldman Sachs first reported a position in BLTE in Q4 2024 and has held it in 4 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Goldman Sachs held 105,509 shares of Belite Bio worth $16.8M as of Q1 2026.
  • Goldman Sachs bought 60,910 Belite Bio shares in Q1 2026, an estimated $10.2M.
  • Belite Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2600 holding.
  • Goldman Sachs first reported a position in Belite Bio in Q4 2024 and has held it in 4 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.